BioAtla (BCAB) Income from Continuing Operations (2020 - 2026)
BioAtla (BCAB) posted quarterly Income from Continuing Operations of 9291000.0 for Q1 2026, up 46.91% year-over-year from 6324080.5 in Q1 2025, and down 1.19% quarter-over-quarter from 9182000.0 in Q4 2025.
BioAtla (BCAB) Income from Continuing Operations (2020 - 2026) Analysis & Trends
BioAtla's Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 9291000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 46.91% year-over-year to 9291000.0; the TTM figure through Mar 2026 stood at 60023000.0 (up 11.48% YoY), while the FY2025 annual figure was 174394000.0, down 0.67% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 9291000.0, down from 9182000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 9182000.0 in Q4 2025, with the low at 2759502000.0 in Q3 2022.
- The 5-year median for Income from Continuing Operations is 26273000.0 (2025), against an average of 219234764.71.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations sank 11403.2% in 2022, then soared 98.76% in 2023.
- BioAtla's Income from Continuing Operations stood at 27913000.0 in 2022, then grew by 2.65% to 27172000.0 in 2023, then soared by 42.24% to 15695000.0 in 2024, then surged by 41.5% to 9182000.0 in 2025, then dropped by 1.19% to 9291000.0 in 2026.
- Business Quant data shows BCAB's Income from Continuing Operations at 9291000.0 in Q1 2026, 9182000.0 in Q4 2025, and 15277000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | BioAtla | 5.41 Mn | 5.41 Mn | - | 232,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.88 Mn |
| Mar 31, 2026 | -9.29 Mn |
| Dec 31, 2025 | -9.18 Mn |
| Sep 30, 2025 | -15.28 Mn |
| Jun 30, 2025 | -26.27 Mn |
| Mar 31, 2025 | -17.50 Mn |
| Dec 31, 2024 | -15.70 Mn |
| Sep 30, 2024 | -11.85 Mn |
| Jun 30, 2024 | -22.77 Mn |
| Mar 31, 2024 | -472.87 Mn |
| Dec 31, 2023 | -27.17 Mn |
| Sep 30, 2023 | -34.13 Mn |
| Jun 30, 2023 | -133.99 Mn |
| Mar 31, 2023 | -27.86 Mn |
| Dec 31, 2022 | -27.91 Mn |
| Sep 30, 2022 | -2.76 Bn |
| Jun 30, 2022 | -91.08 Mn |
| Mar 31, 2022 | -24.64 Mn |
| Dec 31, 2021 | -24.76 Mn |
| Sep 30, 2021 | -23.99 Mn |